Citations

Clear

1526 citation(s) found for "Sun, Yu".

Twice‐daily administration improves the effectiveness of 0.01% atropine for controlling myopia in slowing axial elongation and refractive progression
Xu, Shengsong , Wang, M Y , Qu, Yan , Jiang, Jinyun , Zhao, Wenchen , Zheng, Bingru , Lei, Xingyu, Li, Zhouyue , Hu, Yin , Wang, Mengyi , Zhou, Fengqi, Zheng, Bingru , Yang, Xiao , Qu, Yiwen, Wang, Yanbin , Zhou, Fengqi , Chen, Weiyin, Lei, Xingyu

Mayo Clinic

Ophthalmic and Physiological Optics | July 23, 2025 | Volume: 45 | Issue: 7 | Pages: 1856-1866

10.1111/opo.13558 | PMID 40698880 Get It

Abstract Purpose It remains unclear whether increasing the frequency of administration of 0.01% atropine improves its effectiveness in slowing axial elongation or refractive progression. This study compared twice‐daily 0.01% atropine administration and traditional once‐nightly administration. Methods A hybrid design was adopted incorporating both retrospective and prospective elements, with participants observed for 1 year. The control group (received saline eye drops) and once‐daily 0.01% atropine group (Atropine‐1 group) were derived from two previous trials, while the twice‐daily 0.01% atropine group (Atropine‐2 group) was enrolled prospectively. A total of 163 participants were included in the intention‐to‐treat set, with 51, 70 and 42 participants in the control, Atropine‐1 and Atropine‐2 groups, respectively. The primary outcome was the change in axial length (AL), and the secondary outcome was the change in cycloplegic spherical equivalent refraction (SER). Results Compared with the control group (0.48 ± 0.22 mm), both Atropine‐1 (0.26 ± 0.17 mm) and Atropine‐2 (0.15 ± 0.18 mm) groups showed significantly reduced AL elongation ( p < 0.001). Notably, Atropine‐2 significantly improved slowing of AL elongation compared with Atropine‐1 ( p = 0.008). The result of the secondary outcome (adjusted SER change) was consistent. Atropine‐2 was significantly more effective in slowing SER progression (−0.15 ± 0.37 D) than Atropine‐1 (−0.41 ± 0.50 D) ( p = 0.02). Based on a multivariable model, age was identified as the key covariate to perform subgroup analyses. In the younger subgroup (8–10 years), AL elongation was significantly reduced in the Atropine‐2 group (0.16 ± 0.17 mm) compared with the Atropine‐1 group (0.36 ± 0.22 mm; p = 0.002). In the older subgroup (10–12 years), there was no significant difference in progression. Consistent results were observed in the sensitivity analyses based on the per‐protocol set. Conclusion Twice‐daily administration of 0.01% atropine was more effective than once daily in slowing AL elongation and SER progression in children 8 to 10 years of age. Further investigation with extended follow‐up is warranted to substantiate this finding.
What Is the Appropriate Sample Size in Human Cadaveric Studies? A Quantitative Review of 770 Articles
Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R. , Kikuchi, Keishiro, Kim, Chung Yoh , Ono, Kisho , D'Antoni, Anthony, Komune, Noritaka , Kitagawa, Norio , Kim, Hee‐Jin , Loukas, Marios , Watanabe, Koichi , Tubbs, R. Shane , Iwanaga, Joe , Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R , Kim, Chung Yoh , Ono, Kisho , Komune, Noritaka , Tabira, Yoko , Hur, Mi-Sun , Kim, Hee-Jin , Loukas, Marios , Watanabe, Koichi , Iwanaga, Joe , Cardona, Juan J. , Kikuchi, Keishiro , D’Antoni, Anthony V. , Tabira, Yoko

Mayo Clinic

Clinical Anatomy | July 22, 2025 | Volume: 39 | Issue: 1 | Pages: 14-19

10.1002/ca.70007 | PMID 40692167 Get It

ABSTRACT Determining an appropriate sample size in human cadaveric studies remains a long‐standing and unresolved challenge. Unlike other basic science fields, anatomical research is constrained by factors such as limited human donor availability, cultural considerations, and ethical restrictions. Despite these limitations, researchers are often asked to justify sample sizes, yet no standardized guidelines currently exist. To quantitatively assess sample sizes in recent human cadaveric studies and propose evidence‐based recommendations for future research, a PubMed search was conducted on February 26, 2024, using the term human cadaveric study . The articles published in 2023 and 2024 were screened, yielding 770 eligible studies. Data extracted included the total sample size, number of classified groups, and journal impact factor (IF). Descriptive statistics, linear regression, and correlation analyses were performed. Continuous variables were summarized using medians and interquartile ranges (IQR). The median sample size was 11.5 (IQR: 7–20), and 47.9% of studies used 10 or fewer specimens. The median number of classified groups was 3 (IQR: 2–4). Linear regression showed that studies dividing specimens into 2–6 groups often failed to meet the recommended sample size per group based on regression modeling. No significant correlation was found between sample size and journal IF ( r = −0.062, p = 0.115). Most cadaveric studies rely on small sample sizes due to inherent constraints, yet many still attempt a subgroup analysis without sufficient statistical power. Although flexibility is essential in anatomical research, we recommend a minimum total sample size of 10 for basic studies and at least five samples per group for those involving classification. Cadaveric sample size alone does not predict journal impact, highlighting the importance of methodological rigor over quantity.
A Radiomic Approach to Clinical MRI Refines the Thalamus‐Cognition Link in Multiple Sclerosis
Buyukturkoglu, Korhan , Davis, Levi, Orellana, Renán A., Sun, Rongyi , Özçelik, Sinem , Isenstein, Nina M., Onomichi, Kaho, Iqbal, Rifat, Zhao, B., Stern, Yaakov E. , Zeydan, Burcu , Kantarci, Orhun H. , Jager, Philip L. De , Zeydan, Burcu , Lin, Lu , Davis, Levi, Orellana, Renan E., Iqbal, Rifat, Stern, Yaakov, Riley, Claire

Mayo Clinic

Journal of Neuroimaging | July 21, 2025 | Volume: 35 | Issue: 4 | Pages: No page available

10.1111/jon.70069 | PMID 40685506 Get It

ABSTRACT Background and Purpose Radiomics extracts imaging features that may not be detectable through conventional volumetric analyses. Given their role in multiple sclerosis (MS), we applied radiomics to thalamic nuclei and examined their associations with cognitive performance. Methods A total of 601 individuals were included (342 people with MS [PwMS] from two cohorts and 259 healthy controls [HC]). Radiomic features (RF) and volumes were extracted from the whole thalamus, five thalamic nuclei, and the putamen segmented on three‐dimensional T1‐weighted images. Cognitive performance was assessed using the Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial Addition Test (PASAT) in PwMS and the Digit Symbol Substitution Test (DSST) in HC. In the first MS cohort, multivariate linear regression in a discovery set ( N = 103) identified thalamus‐derived RF associated with SDMT, which were retested in a replication set ( N = 63). Their associations with PASAT in a second MS cohort ( N = 176) and DSST in HC were also evaluated. We then tested whether the same RFs, when extracted from the putamen, was associated with SDMT. Least Absolute Shrinkage and Selection Operator (LASSO) models assessed the combined predictive value of RF and volumes. Results Twenty‐eight RF–region of interest (ROI) pairs were associated with SDMT in the replication set (false discovery rate [FDR] < 0.05). Of these, 24 were also associated with PASAT (FDR ≤ 0.03), and 2 with DSST. Only ventral nuclei volume showed replicated associations among volumetrics. Only four putamen‐derived pairs were associated with SDMT (FDR = 0.04). LASSO results confirmed RF outperformed volumes. Conclusion RF extracted from the thalamus is strongly associated with cognitive performance in PwMS, outperforming volumetric measures and supporting their potential as sensitive imaging biomarkers.
Enhancing cognitive function in breast cancer survivors through community-based aerobic exercise training: protocol for a Hybrid Type I effectiveness–implementation study employing a randomised controlled design
Ehlers, Diane K. , Austin, Jessica D. , Page, Lindsey L. , Porter, Gwenndolyn C. , Hickman, Gabriella, McKim, Paul, Cole, Melissa, Donaldson, Maliyah, Braden, B. Blair , Butterfield, Richard , Baxter, Leslie C. , Ahles, Tim A. , Baxter, Leslie C. , Austin, Jessica D , Ernst, Brenda , Ofori, Edward , Fanning, Jason T. , Hickman, Gabriella, Donaldson, Maliyah, Kunze, Katie L. , Estabrooks, Paul Andrew

Mayo Clinic

BMJ Open | July 14, 2025 | Volume: 15 | Issue: 7 | Pages: e104378

10.1136/bmjopen-2025-104378 | PMID 40659404 Get It

Introduction Despite growing evidence to characterise cancer-associated cognitive decline (CACD) in women with breast cancer, interventions to mitigate CACD are limited. Emerging evidence suggests aerobic exercise may enhance cognition after breast cancer diagnosis and treatment; yet, CACD remains an understudied outcome of exercise, and few high-quality studies have been conducted. In addition to knowledge gaps in effectiveness, the translation of exercise interventions to community settings remains challenging. The Breast cancer Reasoning and Activity INtervention (BRAIN) investigates the effectiveness of aerobic exercise training, delivered in a community-based setting, for improving cognitive function in women with breast cancer and gathers information on the implementation success of the intervention. Methods and analysis This Hybrid Type I effectiveness–implementation study is conducted at an academic medical centre in the southwestern United States in partnership with a non-profit, community health and wellness organisation. The study enrols 160 women diagnosed with stage I–IIIa breast cancer and within 3–36 months of treatment completion into a 1:1 randomised controlled trial. Individuals randomised to the exercise group receive a 6-month, individually tailored aerobic exercise programme delivered by exercise trainers employed at local community fitness centres. The programme is progressive in nature and designed to help participants achieve aerobic exercise levels consistent with guidelines for cancer survivors. Individuals randomise to the control group receive a 6-month health education control intervention delivered virtually by hospital-based health educators. Cognitive performance (primary), self-reported cognition, patient-reported outcomes, physical activity and cardiorespiratory fitness are measured at baseline, 6 months (postintervention) and 12 months (follow-up). Brain structure and function are measured via magnetic resonance imaging (MRI) at baseline and 6 months. Implementation outcomes are defined by the RE-AIM framework, which includes reach, effectiveness, adoption, implementation and maintenance. RE-AIM outcomes are measured at baseline, 6 months, 12 months and ongoing during the study. Ethics and dissemination This study was approved by the Mayo Clinic Institutional Review Board (#23-000020). All participants provide informed consent prior to participation. Findings will be disseminated to scientific, clinical and community audiences through manuscripts, presentations and newsletters. Trial registration number NCT04816006.
Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Swarm, Robert A., Youngwerth, Jeanie, Anițescu, Magdalena , Are, Madhuri , Buga, Sorin , Butler, Taylor, Cleary, James F. , Copenhaver, David, Coyne, Christopher , Craig, David S., Finnes, Heidi D. , Greenlee, Heather , Gupta, Mona, Hansen, Eric, Javed, Saba , Kandil, Enas , Mackey, Sean , McGrath, Kathryn, Moryl, Natalie , Nesbit, Suzanne , Noonan, Michael , Norris, Joseph, Pršić, Elizabeth , Rabow, Michael W. , Rickerson, Elizabeth , Sindt, Jill E. , Vorenkamp, Kevin E. , Cunningham, Rebecca, Gurski, Lisa A., Jones, Frankie, Finnes, Heidi, Agne, Julia L. , Butler, Taylor, Chwistek, Marcin , Gupta, Mona, Javed, Saba , McDonald, Andrew, Noonan, Michael, Paice, Judith A. , SMITH, MICHAEL D. , Bruce, Justine Y. , Yoo, Sun

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0032 | PMID 40639401 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain provide recommendations for the comprehensive management of pain in patients with cancer. This article will focus on methods for screening for pain, safe and appropriate prescription of opioid and miscellaneous analgesics, and the optimization of nonpharmacologic interventions including integrative and interventional strategies for treatment of cancer-related pain. Additionally, the NCCN Guidelines discuss methods for the safe reduction of opioids when appropriate, as well as techniques for encouraging the judicious use of opioids. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional issues that are not covered here, including management of pain during a pain crisis, management of procedure-related pain and anxiety, pain management for cancer survivors, and the use of nonopioid and adjuvant analgesics for cancer-related pain.
DNA2 protein destruction dictates DNA hyperexcision, cGAS–STING activation, and innate immune response in CDK12-deregulated cancers
Peng, Jiang , Wang, Zhijun , Yan, Binyuan , Zhu, Shouhai , Huang, Zhenlin , Zhang, Jianong , Ding, Donglin , Li, Xiang , Wang, Liguo , Jin, Baiye , Pang, Jun, Xia, Dan , Sun, Rui , Yan, Binyuan , Zhu, Shouhai , Wang, Liguo , Lou, Zhenkun , Jin, Baiye , Huang, Rui , Sun, Rui , Wang, Zhijun, Lou, Zhenkun , Jin, Baiye , Pang, Jun , Huang, Haojie , Sun, Rui

Mayo Clinic

Proceedings of the National Academy of Sciences | July 7, 2025 | Volume: 122 | Issue: 28 | Pages: No page available

10.1073/pnas.2413732122 | PMID 40623188 Get It

CDK12 primarily functions as a transcription regulatory cyclin-dependent kinase (CDK) that controls mRNA elongation, splicing, and polyadenylation. The CDK12 gene is implicated in human cancers since it is frequently mutated and/or deleted in prostate and ovarian cancer but paradoxically amplified in breast cancer. Here, we demonstrate that CDK12 promotes serine-933 phosphorylation of DNA2, a nuclease/helicase critical for replication fork stress regulation, and the phosphorylation subsequently facilitates DNA2 polyubiquitination and degradation mediated by the APC/C CDC20 E3 ubiquitin ligase. CDK12 inactivation induces but amplification suppresses genome-wide expression of interferon response and antigen processing and presentation machinery genes in ovarian and breast cancer cells, respectively. Besides causing aberrant DNA2 stabilization, replication stress, genomic instability, and cytosolic double-stranded DNA (dsDNA) accumulation, CDK12 loss also triggers cGAS–STING activation and innate immune response, which can be reversed by forced expression of replication protein A (RPA) subunits or DNA2 depletion. Our findings identify DNA2 as a phosphorylation substrate of CDK12, connecting CDK12 to cell cycle regulation. These data also reveal DNA2 protein destruction as a critical mechanism that dictates genomic instability, cGAS–STING signaling activation, and innate immune response in CDK12-deregulated cancers.
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma
Abeykoon, Jithma P. , Zhu, Guangli, Hirohashi, Yuna, Moreau, Lisa A. , Mukkavalli, Sirisha , Parmar, Kalindi , Zambrano, Gabriella, Jiang, Lige, Gwin, Kimberly, King, Rebecca L. , Wu, Xiaosheng , Yi, Dongni , Asada, Shuhei , Zhu, Guangli, Iyer, Divya , Zambrano, Gabriella, Manske, Michelle K. , Cerhan, James R. , Lou, Zhenkun , Shapiro, Geoffrey I. , Witzig, Thomas E. , D’Andrea, Alan D.

Mayo Clinic

Journal of Clinical Investigation | July 3, 2025 | Volume: 135 | Issue: 17 | Pages: No page available

10.1172/jci193006 | PMID 40608419 Get It

Oncogene expression can cause replication stress (RS), leading to DNA double-strand breaks (DSBs) that require repair through pathways such as homologous recombination, nonhomologous end-joining, and microhomology-mediated end-joining (MMEJ). Cyclin D1 (encoded by CCND1 ) is a well-known oncoprotein overexpressed in cancer; however, its role in RS is unknown. Using mantle cell lymphoma (MCL) as a naturally occurring model of cyclin D1 overexpression, we examined the impact of cyclin D1 on RS and DSB repair mechanisms. Cyclin D1 overexpression elevated RS, increased DNA damage, especially during mitosis, and caused specific upregulation of MMEJ. Furthermore, cyclin D1 activated polymerase theta ( POLQ ) transcription by binding its promoter loci, driving POLΘ-mediated MMEJ that is essential to withstand cyclin D1–induced RS. Moreover, concurrent ATM deficiency further intensified RS, enhanced POLQ expression, and heightened reliance on MMEJ-mediated DNA damage repair. Consequently, inhibition of POLΘ in cyclin D1–overexpressed settings further exacerbated RS, causing single-strand DNA gap accumulations and chromosomal instability, ultimately leading to apoptosis, an effect amplified in ATM-deficient cells. Targeting MMEJ via POLΘ inhibition is therefore an effective strategy in the context of cyclin D1 overexpression and ATM deficiency and may provide a unique therapeutic approach for treating MCL and other malignancies characterized by similar alterations.
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Liu, Matthew , Steen, Sanna , Tsiknakis, Nikolaos, Vidal, Joan Martínez , Maher, Nigel G. , Tan, Samuel , Bai, Yalai , Wong, Pok Fai , Gavirelatou, Niki, He, Mengni , Barna, Robert , Bosić, Martina , Bräutigam, Konstantin , Chenhao, Zhou, Gama, João Martins , Kreis, Bianca, Mohácsi, Réka , Pillar, Nir , Poulios, Christos , Toli, Maria Angeliki , Tzoras, Evangelos , Bracero, Yadriel , Bosisio, Francesca M. , Fortarezza, Francesco , Gonzalez, Mercedes Solorzano, Gullo, Irene , Gutiérrez, Francisco Javier Queipo , Hacıhasanoğlu, Ezgi , Jović, Viktor , Lazar, Bianca Andreea, Neppl, Christina, Pinto, Daniel , Plótár, Vanda, Rau, Tilman T. , Skok, Kristijan , Sun, Wenwen , Solaß, Wiebke , Szymoński, K , Thimm, Franziska , Vignati, Danielle, Vigdorovits, Alon , Prieto, Víctor G. , Sinnberg, Tobias , Wilmott, James S. , Cowper, Shawn E. , Hartman, Johan , Osman, Iman , Ács, Balázs , Nourmohammadi, Saeed, Acs, Balazs , Hartman, Johan , Aung, Thazin Nwe , Su, David , Shafi, Saba , Boyacı, Ceren , Tsiknakis, Nikos , Micevic, Goran , Vesely, Matthew D. , Nourmohammadi, Saeed , Djureinovic, Dijana , Bates, Katherine, Chan, Nay Nwe Nyein , Burela, Sneha , Illa-Bochaca, Irineu , Kreis, Bianca, Pinto, João Correia , Cserni, Gábor , Dema, Alis Liliana Carmen , Gonzalez, Mercedes Solorzano, Olincă, Maria , Oliveira, Rui Caetano , Pezzuto, Federica , Pop, Ovidiu Laurean , Serbes, Ezgi Dicle , Stanowska, Olga , Szász, Attila Marcell , Warrell, Jonathan , Saenger, Yvonne M. , Plummer, Jasmine , Rimm, David L.

Mayo Clinic

JAMA Network Open | July 3, 2025 | Volume: 8 | Issue: 7 | Pages: e2518906

10.1001/jamanetworkopen.2025.18906 | PMID 40608341 Get It

Importance Tumor-infiltrating lymphocytes (TILs) are a provocative biomarker in melanoma, influencing diagnosis, prognosis, and immunotherapy outcomes; however, traditional pathologist-read TIL assessment on hematoxylin and eosin–stained slides is prone to interobserver variability, leading to inconsistent clinical decisions. Therefore, development of newer TIL scoring approaches that produce more reliable and consistent readouts is important. Objective To evaluate the analytical and clinical validity of a machine learning algorithm for TIL quantification in melanoma compared with traditional pathologist-read methods. Design, Setting, and Participants This multioperator, global, multi-institutional prognostic study compared TIL scoring reproducibility between traditional pathologist-read methods and an artificial intelligence (AI)-driven approach. The study was conducted using retrospective cohorts of patients with melanoma between January 2022 and June 2023 across 45 institutions, with tissue evaluated by participants from academic, clinical, and research institutions. Participants were selected to ensure diverse expertise and professional backgrounds. Main Outcomes and Measures Intraclass correlation coefficient (ICC) values were calculated for the manual and AI-assisted arms using log-transformed data. Kendall W values were calculated for Clark scores (brisk = 3, nonbrisk = 2, and sparse = 1). Reliabilities of ICC and W values were classified as moderate (0.40-0.60), good (0.61-0.80), or excellent (&amp;gt;0.80). AI TIL measurements were dichotomized using the 16.6 and median cutoffs. Univariable and multivariable Cox regression analyses assessed the prognostic value of TIL scores adjusted for clinicopathologic variables. Results There were 111 patients with melanoma in the independent testing cohort (median [range] age at diagnosis, 61.0 [25.0-87.0] years; 56 [50.5%] male) who contributed melanoma whole tissue sections. A total of 98 participants evaluated TILs on 60 hematoxylin and eosin–stained melanoma tissue sections. All 40 participants in the manual arm were pathologists, while the AI-assisted arm included 11 pathologists and 47 nonpathologists (scientists). The AI algorithm demonstrated superior reproducibility, with ICCs higher than 0.90 for all machine learning TIL variables, significantly outperforming manual assessments (ICC, 0.61 for AI-derived stromal TILs vs Kendall W , 0.44 for manual Clark TIL scoring). AI-based TIL scores showed prognostic associations with patient outcomes (n = 111) using the median cutoff approach with a hazard ratio (HR) of 0.45 (95% CI, 0.26-0.80; P = .005), and using the cutoff of 16.6, with an HR of 0.56 (95% CI, 0.32-0.98; P = .04). Conclusions and Relevance In this prognostic study of TIL quantification in melanoma, the AI algorithm demonstrated superior reproducibility and prognostic associations compared with traditional methods. Although the retrospective nature of the cohorts limits demonstration of clinical utility, the publicly available dataset and open-source AI tool offer a foundation for future validation and integration into melanoma management.
COVID-19 and Cognitive Change in a Community-Based Cohort
Pike, James Russell , Sun, Yifei , Wu, Christina , Suchy‐Dicey, Astrid M. , Elkind, Mitchell S.V., Kucharska‐Newton, Anna , Levine, Deb, Lutsey, Pamela L. , Mosley, Thomas H. , Palta, Priya, Coresh, Josef, Oelsner, Elizabeth C. , Lutsey, Pamela L , Pike, James R , Oelsner, Elizabeth C , Kucharska-Newton, Anna M , Demmer, Ryan T. , Cornelius, Talea M. , Kraal, A. Zarina , Balte, Pallavi , Wu, Chaoqi, Allen, Norrina B. , Cushman, Mary , Howard, Virginia J. , Manly, Jennifer J. , Power, Melinda C. , Seshadri, Sudha , Tracy, Russell P. , Walker, Keenan A.

Mayo Clinic

JAMA Network Open | June 30, 2025 | Volume: 8 | Issue: 6 | Pages: e2518648

10.1001/jamanetworkopen.2025.18648 | PMID 40587126 Get It

Importance SARS-CoV-2 infection has been linked to neurotoxic effects and cognitive deficits. Objective To determine whether decreases in cognitive function were accelerated after SARS-CoV-2 infection compared with individuals not infected. Design, Setting, and Participants Multicenter, prospective cohort study from 2016 to 2022 among 3525 participants alive on March 1, 2020, and enrolled in The Atherosclerosis Risk in Communities (ARIC) study and the Collaborative Cohort of Cohorts for COVID-19 Research study who completed a prepandemic cognitive assessment and a pandemic-era assessment of SARS-CoV-2 infection. Final analyses performed in November 2024. Exposure SARS-CoV-2 infection determined via self-report of a positive SARS-CoV-2 test or health care professional diagnosis of COVID-19, a positive SARS-CoV-2 antinucleocapsid antibody response, or presence of an administrative code for COVID-19 on medical records. Main outcomes and measures A neuropsychological battery assessed multiple cognitive domains, and a cocalibrated confirmatory factor analysis generated factor scores for global cognitive function. The primary outcome was the rate of excess change in cognitive function. Results The 3525 eligible participants had a mean (SD) age of 80.8 (4.7) years, 2085 (59.1%) were female, 752 (21.4%) were Black, and 2773 (78.6%) were White. SARS-CoV-2 infection was detected among 307 participants (8.7%), 103 of whom (33.6%) were hospitalized. Among uninfected participants, the mean annualized change in cognitive function was −0.09 (95% CI, −0.13 to −0.04). Compared with this rate, change was faster (β = −0.06; 95% CI, −0.09 to −0.02) among participants hospitalized for infection, but not different from participants who were infected but not hospitalized (β = 0.00; 95% CI, −0.02 to 0.03). The association among participants hospitalized for infection was evident in the cognitive domains of memory and executive function, but not language. Conclusions and relevance This cohort study of older participants found accelerated decreases in cognition among individuals hospitalized for SARS-CoV-2 infection, but not nonhospitalized infection, in comparison with individuals not yet infected.